A Cell-Based Therapy for Autoimmune Arthritis in a Murine Model
Transcript
Take iPSC-derived regulatory T cells, or Tregs, expressing ovalbumin-specific receptors. Inject them into the tail vein of a restrained mouse.
The cells reach the synovial membrane lining the inner surface of the knee joint capsule.
Next, administer methylated bovine serum albumin or mBSA, emulsified with an adjuvant.
Adjuvants enhance the presentation of mBSA to antigen-presenting cells, or APCs, which process and present the fragments via MHC molecules.
The APCs migrate to the lymph nodes, inducing T cell activation. Activated T cells migrate to the knee joint.
Inject mBSA alone and mBSA with ovalbumin in the left and right knee joints, respectively.
In the left knee, APCs present the mBSA fragments to activated T cells, triggering pro-inflammatory cytokine release and leading to tissue damage and joint swelling, termed arthritis.
In the right knee, Tregs interact with ovalbumin-presenting APCs and release anti-inflammatory cytokines, reducing tissue damage and joint swelling, thereby ameliorating arthritis.
